Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776953 · ClinicalTrials.gov registry record · Phase 4

Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients

A Phase 4 study of Analgesia and Emergencies, sponsored by Hackensack Meridian Health.

Recruiting
Registry status
Phase 4
Development phase
86
Enrollment target
1
Study location

NCT05776953 is a Phase 4 study of Analgesia and Emergencies that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 86 participants, roughly in line with the 88-participant average among 19 other Analgesia trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776953, a Phase 4 study of Analgesia and Emergencies, is actively recruiting participants, sponsored by Hackensack Meridian Health.

RECRUITING
Registry status
Phase 4
Development phase
86 participants
Enrollment target
1
Study location

Study Summary

This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.

Interventions

  • DRUG Ketorolac

Study Locations (1)

New Jersey

  • Hackensack Univarsity medical Center - Hackensack

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2023-12-21
Est. Completion 2026-03-28
Phase Phase 4

Sponsor

Hackensack Meridian Health

90 total trials

What the Registry Record Tells You About NCT05776953

The ClinicalTrials.gov registry entry for NCT05776953 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 88-participant average among 19 other Analgesia trials with a reported enrollment target. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Analgesia appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac is the first listed.

NCT05776953 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT05776953 about?

NCT05776953 is a clinical study titled "Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients". This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.

What is the current status of trial NCT05776953?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2023-12-21. Estimated completion is 2026-03-28.

What conditions does trial NCT05776953 study?

This clinical trial studies the following conditions: Analgesia, Emergencies, Renal Colic, Flank Pain.

What interventions are being tested in trial NCT05776953?

The interventions under investigation include: Ketorolac (DRUG).

Who is sponsoring clinical trial NCT05776953?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776953 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.